News

Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine to pre...

Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine to prevent S.aureus...

Extreme competitive sports - a fitness test for DNA

Unusually high levels of physical exertion do cause oxidative stress, but this does not result in any long-term damage...

US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis...

US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis vaccine

Intercell AG announces Q2/H1 2008 results & gives update on business

Intercell AG announces Q2/H1 2008 results & gives update on business

» International approval processes for Japanese...

SUMO - Publication of the Pichler Group in Molecular Cell

Posttranslational modification with small ubiquitin-related modifier, SUMO, is a widespread mechanism for rapid and...

Intercell AG closes acquisition of IOMAI Corporation

Intercell AG closes acquisition of IOMAI Corporation

» Intercell AG ("Intercell") closes the previously announced...

Affiris and Onepharm listed as promising European biotech companies

This analysis of five biopharmaceutical companies, selected from a pool of 67 European start-ups, is offered by...

IOMAI shareholders approve acquisition by Intercell

IOMAI shareholders approve acquisition by Intercell

» Iomai shareholders voted in favour of the acquisition at the...

Alexander von Gabain: member of EIT governing board

Alexander von Gabain: member of EIT governing board

>> Official appointment of the EIT Governing Board: the European...

Promising new approach to cancer therapy

The research platform Translational Cancer Therapy Research, which was recently established by the Bernhard Keppler and...

Infection of Streptococcus: Unkown receptor molecule responsible for immune response?

Cells of the human immune system recognize the bacterium Streptococcus pyogenes differently from what has been assumed...

Affiris: Milestone reached in clinical trial of Alzheimer's vaccine

Vienna (Austria), 16. July 2008. In the clinical phase I trial AFF001,

AFFiRiS GmbH has now recruited the 24 Alzheimer...